This company listing is no longer active
Sage Therapeutics (SG7) Stock Overview
A biopharmaceutical company, develops and commercializes brain health medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SG7 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sage Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.58 |
| 52 Week High | US$8.90 |
| 52 Week Low | US$4.47 |
| Beta | 0.30 |
| 1 Month Change | -1.89% |
| 3 Month Change | 15.83% |
| 1 Year Change | -14.85% |
| 3 Year Change | -80.07% |
| 5 Year Change | -82.16% |
| Change since IPO | -62.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| SG7 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.3% | -1.6% | 0.6% |
| 1Y | -14.9% | -6.2% | 3.8% |
Return vs Industry: SG7 underperformed the German Biotechs industry which returned -8.6% over the past year.
Return vs Market: SG7 underperformed the German Market which returned 18.6% over the past year.
Price Volatility
| SG7 volatility | |
|---|---|
| SG7 Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: SG7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: SG7's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 353 | Barry Greene | www.sagerx.com |
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders.
Sage Therapeutics, Inc. Fundamentals Summary
| SG7 fundamental statistics | |
|---|---|
| Market cap | €476.05m |
| Earnings (TTM) | -€263.79m |
| Revenue (TTM) | €61.67m |
Is SG7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SG7 income statement (TTM) | |
|---|---|
| Revenue | US$70.41m |
| Cost of Revenue | US$233.26m |
| Gross Profit | -US$162.85m |
| Other Expenses | US$138.34m |
| Earnings | -US$301.19m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.81 |
| Gross Margin | -231.29% |
| Net Profit Margin | -427.77% |
| Debt/Equity Ratio | 0% |
How did SG7 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/01 22:03 |
| End of Day Share Price | 2025/07/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sage Therapeutics, Inc. is covered by 9 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| null null | BMO Capital Markets Equity Research |
| Gary Nachman | BMO Capital Markets Equity Research |